Cargando…
72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension
INTRODUCTION: The long-term safety of dimethyl fumarate (DMF) in patients with relapsing-remitting multiple sclerosis (RRMS) has been studied in mainly Caucasian patients. The present interim analysis aimed to evaluate the 72-week safety of DMF in Japanese patients with RRMS. METHODS: Safety data of...
Autores principales: | Ochi, Hirofumi, Niino, Masaaki, Onizuka, Yasuhiro, Hiramatsu, Katsutoshi, Hase, Masakazu, Yun, Jang, Matta, André, Torii, Shinichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182629/ https://www.ncbi.nlm.nih.gov/pubmed/30206820 http://dx.doi.org/10.1007/s12325-018-0788-8 |
Ejemplares similares
-
Efficacy and safety of dimethyl fumarate in treatment-naïve Japanese
patients with multiple sclerosis: Interim analysis of the randomized
placebo-controlled study
por: Mori, Masahiro, et al.
Publicado: (2019) -
Efficacy of dimethyl fumarate in Japanese multiple sclerosis patients: interim analysis of randomized, double-blind APEX study and its open-label extension
por: Kondo, T, et al.
Publicado: (2019) -
Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020) -
Lymphocyte subtypes in relapsing–remitting multiple sclerosis patients treated with dimethyl fumarate
por: Chaves, C, et al.
Publicado: (2017) -
Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets
por: Lundy, Steven K., et al.
Publicado: (2016)